Yohimbine derivatives and use thereof

Details Yohimbine derivatives and use thereof Yohimbine derivatives and use thereof

2005-08-23

2008-12-30

Aulakh, Charanjit S (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S053000, C546S050000, C435S007200

Reexamination Certificate

active

07470703

ABSTRACT:
Yohimbine derivatives are disclosed having modification of the C-16 carboxyl group to include a sidechain and where the resulting derivative does not possess a second yohimbine pharmacophore (i.e., the compound is not a yohimbine dimer). The yohimbine derivatives of the present invention are preferably characterized by selective activity as α2c-AR antagonists. Use of the compounds, or pharmaceutical composition containing them, for treating or preventing an α2cadrenergic receptor mediated condition or disorder, and for antagonizing activity of an α2cadrenergic receptor are also disclosed.

REFERENCES:
patent: 3940387 (1976-02-01), Saint-Ruf et al.
patent: 6638943 (2003-10-01), Miller et al.
Dossin, O. et al.: Characterization of a new radioiodinated probe for the alpha2C adrenoceptor in the mouse brain. Neurochem. Int. vol. 36, pp. 7-18, 2000.
Lanier, S. M. et al.: Synthesis and characterization of a high affinity radioiodinated probe for the alpha2-adrenergic receptor. Molecular Pharmacol. vol. 29, pp. 219-227, 1986.
Zheng et al., “Yohimbine Dimers Exhibiting Binding Selectivities for Human α2a-versus α2b-Adrenergic Receptors,”Biorg. Med. Chem. Lett.10:627-630 (2000).
Portoghese et al., “Stereostructure-Activity Relationship of Opioid Agonist and Antagonist Bivalent Ligands. Evidence for Bridging between Vicinal Opioid Receptors,”J. Med. Chem.28(9):1140-1141 (1985).
Erez et al., “Narcotic Antagonistic Potency of Bivalent Ligands Which Contain β-Naltrexamine. Evidence for Bridging between Proximal Recognition Sites,”J. Med. Chem.25(7):847-849 (1982).
Portoghese, P.S., “The Role of Concepts in Structure-Activity Relationship Studies of Opioid Ligands,”J. Med. Chem.35(11):1927-1937 (1992).
Portoghese et al., “Bivalent Ligands and the Message-Address Concept in the Design of Selective Opioid Receptor Antagonists,”TIPS Review10:230-235 (1989).
Shimohigashi et al., “Dimeric Tetrapeptide Enkephalins Display Extraordinary Selectivity for the δ Opiate Receptor,”Nature297:333-335 (1982).
LeBoulluec et al., “Bivalent Indoles Exhibiting Serotonergic Binding Affinity,”Bioorganic&Medicinal Chemistry Letters5(2):123-126 (1995).
Cwirla et al., “Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine,”Science276:1696-1699 (1997).
Uhlén et al., “Membrane Organization and Mobility of α2Adrenergic Receptors in MDCK Cells,”Pharmacology Communications6(1-3):155-167 (1995).
Maggio et al., “Coexpression Studies with Mutant Muscarinic/Adrenergic Receptors Provide Evidence for Intermolecular “Cross-Talk” between G-Protein-Linked Receptors,”Proc. Natl. Acad. Sci. USA90:3103-3107 (1993).
Maggio et al., “Functional Role of the Third Cytoplasmic Loop in Muscarinic Receptor Dimerization,”J. Biol. Chem.271(49):31055-31060 (1996).
Pigini et al., “Imidazoline Receptors: Qualitative Structure-Activity Relationships and Discovery of Tracizoline and Benazoline. Two Ligands with High Affinity and Unprecedented Selectivity,”Bioorganic&Medicinal Chemistry5(5):833-841 (1997).
Pigini et al., “Structure-Activity Relationship at α-Adrenergic Receptors Within a Series of Imidazoline Analogues of Cirazoline,”Bioorganic&Medicinal Chemistry8:883-888 (2000).
Gentili et al., “α2-Adrenoreceptors Profile Modulation and High Antinociceptive Activity of (S)-(-)-2-[1-(Biphenyl-2-yloxy)ethy1]-4,5-dihydro-1H-imidazole,”J. Med. Chem.45:32-40 (2002).
Gentili et al., “Imidazoline Binding Sites (IBS) Profile Modulation: Key Role of the Bridge in Determining I1-IBS or I2IBS Selectivity within a Series of 2-Phenoxymethylimidazoline Analogues,”J. Med. Chem.46:2169-2176 (2003).
Gentili et al., “α2-Adrenoreceptors Profile Modulation. 2.1Biphenyline Analogues as Tools for Selective Activation of the α2C-Subtype,”J. Med. Chem.47:6160-6173 (2004).
Lalchandani et al., “Yohimbine Dimers Exhibiting Selectivity for the Human α2C-Adrenoceptor Subtype,”The Journal of Pharmacology and Experimental Therapeutics303(3):979-984 (2002).
Bavadekar et al., American Chemical Society 2004 Meeting (2004), abstract 60.
Bavadekar et al., “MonomericYohimbine Analogs as Selective Human Alpha 2C-Adrenergic Receptor Ligands,”Experimental Biology 2004Abstract #164.10 (2004).
Mustafa et al., “Synthesis and Biological Studies of Yohimbine Derivatives on Human α2C-Adrenergic Receptors,”Bioorganic&Medicinal Chemistry Letters15:2758-2760 (2005).

Affiliated with

Also associated with

Rating

Yohimbine derivatives and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Yohimbine derivatives and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Yohimbine derivatives and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4022680